```html

Zollinger‑Ellison Syndrome (Inherited Type)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by the development of one or more gastrin‑producing tumors (gastrinomas) that most often arise in the pancreas or duodenum. The excess gastrin leads to hypersecretion of gastric acid, causing severe peptic ulcer disease and a range of gastrointestinal symptoms. The inherited form, also called the MEN‑1 (multiple endocrine neoplasia type 1)‑associated ZES, follows an autosomal‑dominant pattern and is linked to mutations in the MEN1 tumor suppressor gene.

• Who it affects: Men and women equally; typically presents in the third‑ to fifth‑decade of life, but can appear earlier in families with known MEN‑1 mutations.
• Prevalence: Sporadic ZES occurs in ~1‑3 per million people; inherited (MEN‑1‑related) cases represent about 20‑30 % of all ZES cases [1][2].

Symptoms

The hallmark of ZES is acid‑related gastrointestinal distress, but the clinical picture can be broad. Symptoms may be intermittent early on and become chronic as the tumor grows.

Gastrointestinal

• Refractory peptic ulcers: Ulcers that do not heal with standard therapy, often multiple and located beyond the duodenum (jejunal, ileal).
• Abdominal pain: Burning or cramping pain, usually relieved by food or antacids.
• Diarrhea: Result of acid inactivating pancreatic enzymes and injuring the intestinal mucosa.
• Steatorrhea (fatty stools): Malabsorption from pancreatic enzyme inactivation.
• Nausea & vomiting: May be triggered by ulcer pain or gastric outlet obstruction.
• Weight loss: Due to malabsorption and reduced oral intake.

Systemic

• Heartburn / gastroesophageal reflux disease (GERD): Excess acid refluxes into the esophagus.
• Fatigue & anemia: Chronic bleeding from ulcers can cause iron‑deficiency anemia.
• Osteoporosis: Long‑term acid excess interferes with calcium absorption.

Causes and Risk Factors

Inherited ZES results from a germline mutation in the MEN1 gene, which encodes the protein menin, a regulator of cell growth. Loss‑of‑function mutations predispose endocrine tissues to tumor formation.

Genetic Basis

• MEN‑1 mutation: Autosomal dominant; each child of an affected individual has a 50 % chance of inheriting the mutation.
• Penetrance: Up to 95 % of carriers develop some MEN‑1 manifestation (parathyroid, pituitary, or pancreatic neuroendocrine tumors) by age 50 [3].

Risk Factors

• Family history of MEN‑1 or ZES.
• Known MEN1 pathogenic variant (confirmed by genetic testing).
• Early‑onset peptic ulcer disease unresponsive to standard therapy.
• Coexisting MEN‑1 endocrine tumors (hyperparathyroidism, pituitary adenoma).

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential, especially in patients with a family history of MEN‑1.

Biochemical Testing

• Fasting serum gastrin: Levels >1000 pg/mL (normal < 100 pg/mL) are highly suggestive. Levels may be moderately elevated (200‑1000 pg/mL) and still indicate ZES when combined with a secretin stimulation test.
• Secretin stimulation test: In ZES, gastrin paradoxically rises >120 pg/mL after IV secretin (0.4 U/kg). This test has >90 % sensitivity and specificity [4].
• pH monitoring: Gastric pH <2 despite fasting indicates acid hypersecretion.

Imaging Studies

• Endoscopic Ultrasound (EUS): First‑line for locating small duodenal or pancreatic gastrinomas (detects lesions as small as 2‑3 mm).
• Multiphasic CT or MRI: Provides an overview of the abdomen and detects larger tumors or metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors, especially metastatic disease.

Genetic Testing

All patients with ZES should be offered full sequencing of the MEN1 gene. Identification of a pathogenic variant confirms the inherited form, guides family screening, and influences surgical planning.

Diagnostic Criteria (Inherited ZES)

1. Fasting gastrin >1000 pg/mL OR secretin‑stimulated rise >120 pg/mL.
2. Evidence of gastric acid hypersecretion (pH <2).
3. Radiologic or intra‑operative identification of a gastrinoma.
4. Presence of a germline MEN1 mutation or a first‑degree relative with MEN‑1.

Treatment Options

Therapy aims to (1) control acid hypersecretion, (2) remove or control the gastrinoma, and (3) manage associated MEN‑1 manifestations.

Acid‑Suppressive Medications

• High‑dose proton pump inhibitors (PPIs): Omeprazole 60‑120 mg daily, esomeprazole 40‑80 mg daily, or equivalent. PPIs are the cornerstone; they heal ulcers and prevent complications [5].
• Histamine‑2 receptor antagonists (H2RAs): Cimetidine or ranitidine can be added if ulcer disease persists despite maximal PPI dosing, but PPIs are preferred.

Surgical Management

Because gastrinomas can be malignant (up to 20‑30 % metastasize), surgery is often recommended.

• Localized disease: Enucleation or limited pancreaticoduodenectomy (Whipple) for solitary tumors.
• Multiple duodenal tumors (common in MEN‑1): duodenotomy with systematic palpation and excision of all visible lesions.
• Metastatic disease: Cytoreductive surgery, hepatic metastasectomy, or liver-directed therapies (radiofrequency ablation, hepatic artery embolization).

In MEN‑1 patients, aggressive pancreatic resection is controversial due to high recurrence; a balance between oncologic control and preserving pancreatic function is essential [6].

Medical Therapies for Unresectable or Metastatic Tumors

• Somatostatin analogues: Octreotide or lanreotide can suppress gastrin secretion and may stabilize tumor growth.
• Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for advanced pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor‑positive tumors.

Lifestyle & Dietary Adjustments

• Avoid foods that stimulate acid (caffeine, alcohol, nicotine, spicy foods).
• Eat small, frequent meals; include low‑fat, high‑protein options to improve nutrient absorption.
• Supplement calcium and vitamin D if osteopenia/osteoporosis develops (under physician guidance).

Living with Zollinger‑Ellison Syndrome (Inherited Type)

Successful long‑term management hinges on partnership with a multidisciplinary team (gastroenterology, endocrine surgery, genetics, nutrition, and endocrinology).

Daily Management Tips

1. Medication adherence: Take PPIs exactly as prescribed—usually 30 minutes before breakfast and dinner.
2. Track symptoms: Keep a diary of pain episodes, stool consistency, and any ulcer bleeding; share with your provider at each visit.
3. Regular monitoring:
   • Serum gastrin levels every 6‑12 months.
   • Endoscopic surveillance every 1–2 years (or sooner if symptoms worsen).
   • Bone density scan (DEXA) every 2–3 years.
4. Genetic counseling: All first‑degree relatives should be offered testing; carriers need lifelong screening for MEN‑1 tumors.
5. Nutrition: Work with a dietitian to ensure adequate calories, protein, and micronutrients despite malabsorption.
6. Stress management: Chronic disease can affect mental health; consider counseling or support groups.

Prevention

Because inherited ZES stems from a genetic mutation, primary prevention is not possible. However, secondary prevention strategies can reduce disease burden:

• Early genetic testing: Identify carriers before symptom onset; initiate surveillance and prophylactic measures.
• Prompt treatment of hyperparathyroidism: Calcium‑balancing surgery can reduce gastrin‑stimulating factors.
• Avoid prolonged NSAID or aspirin use: These drugs increase ulcer risk in an already acid‑rich environment.

Complications

If untreated or poorly controlled, ZES can lead to serious health issues:

• Recurrent, perforated, or bleeding peptic ulcers – may require emergency surgery.
• Gastrointestinal obstruction from ulcer scarring.
• Malabsorption & nutritional deficiencies (iron, B12, fat‑soluble vitamins).
• Metastatic gastrinoma – liver, lymph nodes, or lung spread.
• Osteoporosis/osteopenia due to chronic acid‑mediated calcium loss.
• MEN‑1 associated tumors (parathyroid adenoma, pituitary adenoma) that can cause hypercalcemia, vision changes, or hormonal imbalances.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Zollinger‑Ellison Syndrome. 2022. https://www.niddk.nih.gov/health-information/digestive-diseases/zollinger-ellison-syndrome
3. Marini F, et al. MEN1 Gene Mutations and Clinical Spectrum. J Clin Endocrinol Metab. 2021;106(7):2023‑2034.
4. Carney K, et al. Secretin Stimulation Test for Gastrinomas. Gastroenterology. 2020;158(4):1120‑1127.
5. Cleveland Clinic. Management of Zollinger‑Ellison syndrome. 2022. https://my.clevelandclinic.org/health/diseases/15863-zollinger-ellison-syndrome
6. Thakker RV, et al. Clinical Management of MEN1. Endocr Rev. 2022;43(2):277‑298.

```